Encouraging Phase III Clinical Data of Adamgammadex Presented at the 2024 WCA

HANGZHOU, China, March 5, 2024-The18^th World Congress of Anesthesiologists (WCA), organized by the World Federation of Societies of Anesthesiologists (WFSA), was held in Singapore from March 3^rd to 7^th, 2024. With delegates from more than 130 countries, the WCA is the only international congress offering a comprehensive program on global anesthesiology.

Professor Liu Jin from West China Hospital, Sichuan University, was invited to share his keynote report on "Anesthetic Drug Innovation and Development: Present and Future in China." In his report, Professor Liu highlighted the encouraging phase III clinical data of Adamgammadex, which received an enthusiastic response from the audience.

Adamgammadex (Aom0498) is the next generation of specific neuromuscular blockade antagonists and has been shown to rapidly reverse neuromuscular blockades induced by rocuronium at various depths within 3 minutes. Compared to Sugammadex, Adamgammadex has a lower incidence of severe adverse reactions, such as allergic reactions, neuromuscular blockade recurrence, bradycardia, and laryngospasm, while maintaining more stable efficacy.

Adamgammadex has completed a Pre-NDA meeting with the Centre of Drug Evaluation (CDE) of China and an End of Phase II Meeting with the FDA of the United States. It will submit a new drug application in China in the second quarter of 2024 and will be codeveloped and copromoted with our partner globally in the future.

About Aomo

Aomo Pharma, Inc. (the US branch of Adamerck), is dedicated to the research of innovative drugs with independent intellectual property rights that are urgently needed globally. Adhering to the corporate mission of "Better Drugs for Better Lives", we have devoted more than two decades to the research and development of new drugs. Currently, our company boasts a pipeline of more than ten innovative drugs with independent intellectual property rights. These products span various application fields, such as anesthesia, cardiovascular and cerebrovascular surgery, and ophthalmology. We are engaged in the commercial development of these products on a global scale, and they hold significant clinical value and broad market prospects. Among these, Aom0498 has entered the Pre-NDA phase and is expected to become the only patented drug globally in the muscle relaxation antagonist field. Aom0499, Aom0319, and Aom0315 have all entered clinical studies at both the international and national levels, with pipeline advancements in Phases I to III. Our company continues to embrace the philosophy of innovative development, focusing on the innovative design of drugs and the industrialization of new drug development as our core competitive strengths. We are committed to continuously promoting the research, development, and market launch of new drugs with independent intellectual property rights, aspiring to become a global leader in the pharmaceutical industry within our specialized fields.